Jaguar Health Announces 1-for-25 Reverse Stock Split
Jaguar Health announced a 1-for-25 reverse stock split intended to support compliance with Nasdaq listing standards, with split-adjusted trading expected to begin on November 24, 2026.
Jaguar Health, Inc. (Nasdaq:JAGX) has announced plans for a 1-for-25 reverse stock split of its issued and outstanding voting common stock. The company said the action is intended to support compliance with Nasdaq's listing standards and follows approval by stockholders at its November 2026 Special Meeting of Stockholders.
The reverse stock split is scheduled to take effect at 12:01 am Eastern Time on Tuesday, November 24, 2026. Jaguar Health expects its common stock to begin trading on a split-adjusted basis when the market opens on that date.
The shares are expected to continue trading on The Nasdaq Capital Market under the symbol “JAGX.” The company has identified the expectation regarding split-adjusted trading as a forward-looking statement subject to risks, uncertainties and assumptions.
Under the announced ratio, every 25 shares held immediately before the Effective Date will be automatically reclassified as one share of common stock. The company said the par value per share will not change.
Jaguar Health will not issue fractional shares in the reverse stock split. Stockholders who would otherwise receive a fractional share will instead receive a cash payment in lieu of that share.
Equiniti Trust Company, LLC is serving as the exchange agent. It will provide instructions to stockholders of record who hold paper stock certificates and need to exchange them for post-split shares.
Stockholders whose shares are held through brokerage accounts or in “street name” are not required to take action to complete the exchange, according to the company.
The new CUSIP number for Jaguar Health's common stock following the reverse stock split is 47010C839.
The reverse stock split follows approval of a proposal presented at Jaguar Health's November 2026 Special Meeting of Stockholders. Details of the proposal were included in the company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on October 8, 2026.
Jaguar Health develops proprietary prescription drugs derived from plants for people with complicated gastrointestinal disease states. Its family companies include Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A., which focus on crofelemer powder for oral solution for rare and orphan gastrointestinal disorders involving intestinal failure. Magdalena Biosciences, a joint venture between Jaguar and Filament Health Corp., is focused on plant-derived prescription medicines for mental health indications.
Jaguar Health, Inc. announced that it will effect a reverse stock split of its issued and outstanding voting common stock at an exchange ratio of 1-for-25. The company said the reverse stock split is intended to support compliance with Nasdaq's listing standards.
Jaguar Health, Inc. announced the reverse stock split on November 20, 2026.
Jaguar Health, Inc. said the reverse stock split will take effect at 12:01 am Eastern Time on Tuesday, November 24, 2026, the Effective Date.
The reverse stock split ratio for Jaguar Health, Inc. is 1-for-25. Every twenty-five (25) shares held immediately before the Effective Date will be automatically reclassified into one (1) share of common stock, without any change in the par value per share.
Jaguar Health, Inc. said its common stock will begin trading on a split-adjusted basis when the market opens on November 24, 2026. The shares will remain listed on The Nasdaq Capital Market under the symbol "JAGX".
The new CUSIP number for Jaguar Health, Inc.'s common stock following the reverse stock split is 47010C839.
The reverse stock split follows approval of a proposal submitted to Jaguar Health, Inc. stockholders at the company's November 2026 Special Meeting of Stockholders. The proposal was described in the company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on October 8, 2026.
Jaguar Health, Inc. said no fractional shares will be issued as a result of the reverse stock split. Stockholders who would otherwise be entitled to a fractional share will receive a cash payment in lieu of that share.
Stockholders of Jaguar Health, Inc. who hold their shares in brokerage accounts or "street name" are not required to take action to effect the exchange. Equiniti Trust Company, LLC, the exchange agent, will send instructions to stockholders of record who hold stock certificates regarding the exchange of their certificates for post-reverse stock split shares.
Jaguar Health, Inc. develops proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal disease states. Its family companies focus on novel crofelemer powder for oral solution for rare and orphan gastrointestinal disorders with intestinal failure, while Magdalena Biosciences focuses on plant-derived prescription medicines for mental health indications.
Jaguar Health, Inc. expects its common stock to begin trading on a split-adjusted basis when the market opens on the Effective Date, November 24, 2026. The company identifies this expectation as a forward-looking statement subject to risks, uncertainties and assumptions.